Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

IV Antibiotic Use during Autologous Hematopoietic Stem Cell Transplantation Is Associated with Inferior Survival in Patients with Multiple Myeloma

Matthew Gromowsky, Zhubin Gahvari, Robin High, Natalie Callander, Christopher D'Angelo

Blood (2022) 140 (Supplement 1): 7716–7717.

https://doi.org/10.1182/blood-2022-163359

Published: 2022

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 4431–4433.

https://doi.org/10.1182/blood-2022-160381

Published: 2022

Journal Articles

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Timothy Martin Schmidt, Rebecca Silbermann, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Natalie Callander, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10077–10078.

https://doi.org/10.1182/blood-2022-164930

Published: 2022

Journal Articles

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Gary J. Schiller, Sascha A. Tuchman, Natalie Callander, Muhamed Baljevic, Adrianna C Rossi, Rami Kotb, Darrell J White, Nizar J. Bahlis, Heather J. Sutherland, Sumit Madan, Richard Leblanc, Christopher P. Venner, William I. Bensinger, Dane R. Van Domelen, Chris Zhang, Ohad S. Bentur, Brea Lipe

Blood (2022) 140 (Supplement 1): 10050–10053.

https://doi.org/10.1182/blood-2022-158011

Published: 2022

Journal Articles

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Salyka M. Sengsayadeth, Bridget Fitzgerald, Bharat Nandakumar, Bicky Thapa, Timothy Martin Schmidt, Rebecca Silbermann, Heidi Chen, Saurabh Chhabra, Natalie Callander, Shaji K Kumar, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10033–10035.

https://doi.org/10.1182/blood-2022-169589

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses

Evan Flietner, Mei Yu, Adhithi Rajagopalan, Yun Zhou, Yubin Feng, Anthony Veltri, Terra Lasho, Zhi Wen, Yuqian Sun, Robert Burns, Mrinal M. Patnaik, Natalie Callander, Fotis Asimakopoulos, Demin Wang, Jing Zhang

Blood (2022) 140 (Supplement 1): 9935–9936.

https://doi.org/10.1182/blood-2022-162827

Published: 2022

Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7275–7277.

https://doi.org/10.1182/blood-2022-156730

Published: 2022

Journal Articles

Immunoregulatory roles of versican proteolysis in the myeloma microenvironment

Chelsea Hope, Simon Foulcer, Justin Jagodinsky, Sarah X. Chen, Jeffrey L. Jensen, Sanjay Patel, Catherine Leith, Ioanna Maroulakou, Natalie Callander, Shigeki Miyamoto, Peiman Hematti, Suneel S. Apte, Fotis Asimakopoulos

Blood (2016) 128 (5): 680–685.

https://doi.org/10.1182/blood-2016-03-705780

Published: 2016

Includes: Supplemental data

Journal Articles

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Shaji K. Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey Zonder, Natalie Callander, Rafael Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart

Blood (2015) 125 (3): 443–448.

https://doi.org/10.1182/blood-2014-05-573741

Published: 2015

Journal Articles

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

Chelsea Hope, Samuel J. Ollar, Erika Heninger, Ellen Hebron, Jeffrey L. Jensen, Jaehyup Kim, Ioanna Maroulakou, Shigeki Miyamoto, Catherine Leith, David T. Yang, Natalie Callander, Peiman Hematti, Marta Chesi, P. Leif Bergsagel, Fotis Asimakopoulos

Blood (2014) 123 (21): 3305–3315.

https://doi.org/10.1182/blood-2014-02-554071

Published: 2014

Includes: Supplemental data

Journal Articles

Microfluidic Platform Enabling Primary Multiple Myeloma Mono- and Cis -Co-Culture Analysis

Pak Chorom, BA, Edmond WK Young, PhD, Natalie Callander, MD, David J Beebe, PhD, Shigeki Miyamoto, PhD

Blood (2012) 120 (21): 1830.

https://doi.org/10.1182/blood.V120.21.1830.1830

Published: 2012

Journal Articles

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Blood (2012) 120 (21): 3165.

https://doi.org/10.1182/blood.V120.21.3165.3165

Published: 2012

Journal Articles

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, MD, Betsy R. LaPlant, Wee Joo Chng, MD, PhD, Jeffrey A. Zonder, MD, Natalie Callander, MD, Vivek Roy, M.D., Briant Furth, Charles Erlichman, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 76.

https://doi.org/10.1182/blood.V120.21.76.76

Published: 2012

Journal Articles

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Christof Scheid, MD, PhD, Donna Reece, Meral Beksac, MD, Andrew Spencer, MD, Natalie Callander, MD, Pieter Sonneveld, MD, Ghulam Kalimi, PhD, Can Cai, Michael Shi, MD, PhD, Jeffrey W. Scott, A. Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4055.

https://doi.org/10.1182/blood.V120.21.4055.4055

Published: 2012

Journal Articles

Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche

Chelsea Hope, Ellen Hebron, Jaehyup Kim, MD, Jeff Jensen, Claire Flanagan, Neehar Bhatia, Catherine Leith, MBBChir, Ioanna Maroulakou, PhD, Constantine S. Mitsiades, MD, PhD, Shigeki Miyamoto, PhD, Natalie Callander, MD, Peiman Hematti, MD, Fotis Asimakopoulos, MBBChir, PhD

Blood (2012) 120 (21): 443.

https://doi.org/10.1182/blood.V120.21.443.443

Published: 2012

Journal Articles

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Andrew T Humbert, Rachel Cook, MS, MD, Thomas McFarland, Ronald Go, MD, Stephanie Markovina, MD, Shigeki Miyamoto, PhD, Eliot C. Williams, MD, PhD, Fotios Asimakopoulos, MBBChir, PhD, Jill Kolesar, PhD, Michael A. Thompson, MD, PhD, Kyungmann Kim, Natalie Callander, MD

Blood (2012) 120 (21): 5041.

https://doi.org/10.1182/blood.V120.21.5041.5041

Published: 2012

Journal Articles

Optical Mapping of the Myeloma Cancer Genome to Elucidate Mechanisms of Acquired Resistance to Proteasome Inhibitors.

Aditya Gupta, Jaehyup Kim, MD, Chelsea Hope, Jeff Jensen, Natalie Callander, MD, Peiman Hematti, MD, Emery H Bresnick, PhD, David C Schwartz, PhD, Fotis Asimakopoulos, MBBChir, PhD

Blood (2012) 120 (21): 2444.

https://doi.org/10.1182/blood.V120.21.2444.2444

Published: 2012

Journal Articles

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert Rifkin, Jeffrey Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar

Blood (2012) 119 (19): 4375–4382.

https://doi.org/10.1182/blood-2011-11-395749

Published: 2012

NARROW

IV Antibiotic Use during Autologous Hematopoietic Stem Cell Transplantation Is Associated with Inferior Survival in Patients with Multiple Myeloma

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Immunoregulatory roles of versican proteolysis in the myeloma microenvironment

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

Microfluidic Platform Enabling Primary Multiple Myeloma Mono- and Cis -Co-Culture Analysis

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Optical Mapping of the Myeloma Cancer Genome to Elucidate Mechanisms of Acquired Resistance to Proteasome Inhibitors.

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only